Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 9/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643053 | 0.73 | ACLY (0.41) | CNR1CNR2ENPP3CA2ENPP1 | |
| SCHEMBL6231818 | 0.71 | ACLY (0.45) | CNR1KMT2ACNR2HSD11B1ALDH1A1 | |
| SCHEMBL6232295 | 0.69 | LMNA (0.41) | CNR1NPC1KMT2ASMN1; SMN2CNR2 | |
| SCHEMBL6233316 | 0.66 | HSD11B1 (0.39) | KMT2ACA2HSD11B1ALDH1A1MAPT | |
| SCHEMBL5176777 | 0.65 | PTGDR (0.48) | — | |
| SCHEMBL1578125 | 0.56 | FAAH (0.81) | KMT2AFAAHCNR2ALDH1A1MAPT | |
| SCHEMBL1421026 | 0.56 | FAAH (1.00) | KMT2AFAAHCNR2ALDH1A1MAPT | |
| SCHEMBL19863263 | 0.55 | FAAH (0.61) | KMT2AFAAHCNR2ALDH1A1MAPT | |
| SCHEMBL25248699 | 0.55 | EPHX2 (0.67) | NPC1RAB9AKMT2ASMN1; SMN2FAAH | |
| SCHEMBL25808905 | 0.54 | RAB9A (0.53) | NPC1RAB9AKMT2ASMN1; SMN2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1193243-B1 | NOVEL PROCESS FOR PRODUCING BICYCLIC AMINO ALCOHOL | SHIONOGI & CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1808427-A2 | Novel processes for the preparation of bicyclic aminoalcohols | SHIONOGI & CO., LTD. (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7214832-B2 | Processes for the preparation of bicyclic aminoalcohols | SHIONOGI & CO., LTD. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20040171882-A1 | Novel processes for the preparation of bicyclic aminoalcohols | HONMA TSUNETOSHI (JP) | 2004-09-02 | — | — | US | disclosed |
| US-6723857-B1 | NORPINONE TO ITS BENZOTHIOPHENE CARBOXAMIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| EP-1193243-A1 | NOVEL PROCESS FOR PRODUCING BICYCLIC AMINO ALCOHOL | SHIONOGI & CO., LTD. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171882-A1 | Novel processes for the preparation of bicyclic aminoalcohols | DOHH, OXER1, XDH | CNR1 236/4885NPC1 970/4885RAB9A 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.